Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Maravai Lifesciences Holdings (MRVI) Accumulated Expenses (2020 - 2025)

Historic Accumulated Expenses for Maravai Lifesciences Holdings (MRVI) over the last 6 years, with Q3 2025 value amounting to $48.1 million.

  • Maravai Lifesciences Holdings' Accumulated Expenses rose 2374.93% to $48.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $48.1 million, marking a year-over-year increase of 2374.93%. This contributed to the annual value of $39.6 million for FY2024, which is 3430.28% down from last year.
  • As of Q3 2025, Maravai Lifesciences Holdings' Accumulated Expenses stood at $48.1 million, which was up 2374.93% from $50.2 million recorded in Q2 2025.
  • Maravai Lifesciences Holdings' Accumulated Expenses' 5-year high stood at $70.1 million during Q1 2023, with a 5-year trough of $24.8 million in Q2 2021.
  • In the last 5 years, Maravai Lifesciences Holdings' Accumulated Expenses had a median value of $43.6 million in 2022 and averaged $44.4 million.
  • Per our database at Business Quant, Maravai Lifesciences Holdings' Accumulated Expenses soared by 11617.66% in 2023 and then tumbled by 4946.84% in 2024.
  • Over the past 5 years, Maravai Lifesciences Holdings' Accumulated Expenses (Quarter) stood at $34.6 million in 2021, then surged by 54.37% to $53.4 million in 2022, then grew by 12.86% to $60.2 million in 2023, then plummeted by 34.3% to $39.6 million in 2024, then grew by 21.64% to $48.1 million in 2025.
  • Its Accumulated Expenses stands at $48.1 million for Q3 2025, versus $50.2 million for Q2 2025 and $44.6 million for Q1 2025.